LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

NCT ID: NCT00593047

Last Updated: 2008-12-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-11-30
• Study Completion Date: 2008-09-30

Brief Summary

Thyroid hormones are known to reduce cholesterol levels through regulation of a number of key enzymes involved in synthesis, degradation, and lipid transport. However, the currently marketed thyroid agonists are non-selective, and cannot be used for the treatment of hypercholesterolemia due to extrahepatic consequences of hyperthyroidism, especially on heart, bone, and muscle.

To take advantage of thyroid hormone effect on lipid metabolism for the treatment of hypercholesterolemia, it is necessary to develop a selective thyroid receptor agonist that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue. KB2115 is a thyroid agonist developed to be liver selective.

The purpose of the study is to assess the efficacy and safety of KB2115 as add on therapy to low and middle doses of statin following 12 weeks of exposure compared to placebo. The aim of the study is to assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115 at doses between 25 and 100 µg and to define a clinically relevant dose or dose range for future studies.

Conditions

Dyslipidemia

Keywords

hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1

Statin + placebo

Group Type: PLACEBO_COMPARATOR

KB2115

Intervention Type: DRUG

tablet formulation given once daily for 12 weeks

2

Statin + KB2115 dose 1

Group Type: EXPERIMENTAL

KB2115

Intervention Type: DRUG

tablet formulation given once daily for 12 weeks

3

Statin + KB2115 dose 2

Group Type: EXPERIMENTAL

KB2115

Intervention Type: DRUG

tablet formulation given once daily for 12 weeks

4

Statin + KB2115 dose 3

Group Type: EXPERIMENTAL

KB2115

Intervention Type: DRUG

tablet formulation given once daily for 12 weeks

Interventions

KB2115

tablet formulation given once daily for 12 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent

2. Males or females aged 18 to 75 years. Female patients must be non-fertile. To be considered as non-fertile, females must fulfil the following:

• Non-nursing and non-pregnant 12 months prior to enrolment
• Not of child bearing potential ie, either documented irreversible surgically sterile (bilateral oophorectomy or hysterectomy is acceptable, but not tubal ligation) or post-menopausal. Post-menopausal is defined as serum follicle-stimulating hormone (FSH) levels in the post-menopausal range combined with amenorrhea for more than 1 year in a woman above 50 years of age, or amenorrhea for more than 2 years below 50 years of age

3. Patients with hypercholesterolemia treated with stable doses of the below listed lipid lowering medication for at least 3 months prior to randomization

• Atorvastatin not more than 20 mg/day or
• Simvastatin not more than 40 mg/day

4. LDL-cholesterol > 3.0 mmol/L (Week -1)

5. Subject able and willing to comply with all study requirements

6. At randomization, diet as instructed by the investigator during the last 4 weeks prior to randomization and willingness to follow these instructions throughout the study

Exclusion Criteria

1. Cholesterol lowering agents other than the defined statins

2. History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator

3. Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product as judged by the investigator

4. Chronic (> 3 months) pain condition requiring daily medication with pain killers

5. Glycosylated haemoglobin (HbA1c) > 7.0%

6. Diabetes requiring medication other than metformin

7. Clinically abnormal physical findings and laboratory values as judged by the investigator and abnormal resting ECG, eg, QTc interval > 450 msec

8. Body Mass Index of ≥ 40 kg/m2

9. Resent history (< 3 month) of stroke or transient ischemic attacks

10. History of seizure disorder, except febrile convulsions

11. A current diagnosis of cancer, unless in remission

12. Blood pressure (BP) of > 160/95 mm Hg

13. History of cardiac arrhythmia, such as intermittent supraventricular tachyarrhythmia and atrial fibrillation

14. Unstable angina pectoris, myocardial infarction or coronary bypass graft surgery or percutaneous coronary intervention < 6 month before randomization

15. Congestive heart failure New York Heart Association Class > 2

16. Unstable or severe angina pectoris or peripheral artery disease

17. Known thyroid disease or thyroid biomarkers (TSH, T3, free T3, T4, free T4) outside reference range for normal at enrolment and at baseline

18. Positive urine pregnancy test in women at enrolment

19. Use of thyroid replacement therapy and hormone replacement therapy (including contraceptive pills) for last 3 months before randomization

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Karo Bio AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Karo Bio AB

Principal Investigators

Jens Kristensen, MD, PhD

Role: STUDY_DIRECTOR

Karo Bio AB

Locations

Carl-Peter Anderberg

Gothemburg, , Sweden

Countries

Sweden

References

Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010 Mar 11;362(10):906-16. doi: 10.1056/NEJMoa0905633.

Reference Type: DERIVED

PMID: 20220185 (View on PubMed)

Other Identifiers

2007-004413-33

Identifier Type: -

Identifier Source: secondary_id

KBT004

Identifier Type: -

Identifier Source: org_study_id